tiprankstipranks
Vertex Pharmaceuticals Inc. (IT:1VRTX)
NASDAQ:1VRTX
Italy Market
1VRTX
Vertex Pharmaceuticals
RESEARCH TOOLSreports

Vertex Pharmaceuticals (1VRTX) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

1VRTX Analyst Ratings

Strong Buy
24Ratings
Strong Buy
20 Buy
4 Hold
0 Sell
Based on 24 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1VRTX Stock 12 Month Forecast

Average Price Target

€485.46
▲(30.69% Upside)
Based on 24 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is €485.46 with a high forecast of €551.97 and a low forecast of €375.44. The average price target represents a 30.69% change from the last price of €371.45.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"334":"€334","443":"€443","552":"€552","388.5":"€388.5","497.5":"€497.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":551.97142667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€551.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":485.46094052047624,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€485.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":375.44390332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€375.44</span>\n  </div></div>","useHTML":true}}],"tickPositions":[334,388.5,443,497.5,552],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,373,386.76703282076926,400.53406564153846,414.3010984623077,428.0681312830769,441.8351641038462,455.6021969246154,469.36922974538464,483.13626256615385,496.9032953869231,510.67032820769236,524.4373610284615,538.2043938492308,{"y":551.97142667,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,373,381.65084157849816,390.3016831569963,398.95252473549453,407.6033663139927,416.25420789249085,424.905049470989,433.5558910494872,442.2067326279854,450.85757420648355,459.5084157849817,468.1592573634799,476.810098941978,{"y":485.46094052047624,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,373,373.18799256307693,373.37598512615386,373.5639776892308,373.7519702523077,373.9399628153846,374.12795537846154,374.31594794153847,374.5039405046154,374.69193306769233,374.8799256307692,375.06791819384614,375.2559107569231,{"y":375.44390332,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":386.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":384.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":397.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":388.1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":398.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":415.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":388.65,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":365.55,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":373,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€551.97Average Price Target€485.46Lowest Price Target€375.44
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on IT:1VRTX
Brian Abrahams
RBC Capital
RBC Capital
€467.58
Buy
25.88%
Upside
Reiterated
06/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Viatris (NASDAQ: VTRS), Medtronic (NYSE: MDT) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Wells Fargo Analyst forecast on IT:1VRTX
Mohit Bansal
Wells Fargo
Wells Fargo
€473.61
Buy
27.50%
Upside
Reiterated
06/04/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo
Guggenheim Analyst forecast on IT:1VRTX
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
€470.17
Buy
26.58%
Upside
Reiterated
06/02/26
Guggenheim Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on IT:1VRTX
Naz Rahman
Maxim Group
Maxim Group
€495.14
Buy
33.30%
Upside
Reiterated
06/02/26
Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX)
Truist Financial Analyst forecast on IT:1VRTX
Danielle Brill
Truist Financial
Truist Financial
€452.08→€466.72
Buy
25.65%
Upside
Initiated
05/27/26
Vertex Pharmaceuticals assumed with a Buy at TruistVertex Pharmaceuticals assumed with a Buy at Truist
J.P. Morgan Analyst forecast on IT:1VRTX
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
€443.47
Buy
19.39%
Upside
Reiterated
05/20/26
J.P. Morgan Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Barclays Analyst forecast on IT:1VRTX
Eliana Merle
Barclays
Barclays
€522.69→€529.58
Buy
42.57%
Upside
Reiterated
05/06/26
Barclays Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
William Blair Analyst forecast on IT:1VRTX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Addus Homecare (ADUS), Vertex Pharmaceuticals (VRTX)
Oppenheimer Analyst forecast on IT:1VRTX
Jay Olson
Oppenheimer
Oppenheimer
€516.67
Buy
39.09%
Upside
Reiterated
05/05/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Eli Lilly & Co (LLY)
Needham Analyst forecast on IT:1VRTX
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
05/05/26
Analyst Maintains Hold on Vertex as Strong CF Franchise Offsets Mixed Q1 Results and Non‑CF Pipeline Uncertainty
Evercore ISI Analyst forecast on IT:1VRTX
Cory Kasimov
Evercore ISI
Evercore ISI
€456.39→€460.69
Buy
24.03%
Upside
Reiterated
05/05/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Evercore ISI
Stifel Nicolaus Analyst forecast on IT:1VRTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€401.28
Hold
8.03%
Upside
Reiterated
05/05/26
Stifel Nicolaus Remains a Hold on Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on IT:1VRTX
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€376.31→€375.44
Hold
1.08%
Upside
Reiterated
05/05/26
Vertex Pharmaceuticals price target lowered to $436 from $437 at CanaccordVertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
Morgan Stanley Analyst forecast on IT:1VRTX
Terence Flynn
Morgan Stanley
Morgan Stanley
€527→€530.44
Buy
42.80%
Upside
Assigned
05/05/26
Morgan Stanley Remains a Buy on Vertex Pharmaceuticals (VRTX)
TD Cowen Analyst forecast on IT:1VRTX
Phil Nadeau
TD Cowen
TD Cowen
€452.08
Buy
21.71%
Upside
Reiterated
05/05/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Evolus (EOLS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on IT:1VRTX
Brian Abrahams
RBC Capital
RBC Capital
€467.58
Buy
25.88%
Upside
Reiterated
06/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Viatris (NASDAQ: VTRS), Medtronic (NYSE: MDT) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Wells Fargo Analyst forecast on IT:1VRTX
Mohit Bansal
Wells Fargo
Wells Fargo
€473.61
Buy
27.50%
Upside
Reiterated
06/04/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo
Guggenheim Analyst forecast on IT:1VRTX
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
€470.17
Buy
26.58%
Upside
Reiterated
06/02/26
Guggenheim Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on IT:1VRTX
Naz Rahman
Maxim Group
Maxim Group
€495.14
Buy
33.30%
Upside
Reiterated
06/02/26
Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX)
Truist Financial Analyst forecast on IT:1VRTX
Danielle Brill
Truist Financial
Truist Financial
€452.08→€466.72
Buy
25.65%
Upside
Initiated
05/27/26
Vertex Pharmaceuticals assumed with a Buy at TruistVertex Pharmaceuticals assumed with a Buy at Truist
J.P. Morgan Analyst forecast on IT:1VRTX
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
€443.47
Buy
19.39%
Upside
Reiterated
05/20/26
J.P. Morgan Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Barclays Analyst forecast on IT:1VRTX
Eliana Merle
Barclays
Barclays
€522.69→€529.58
Buy
42.57%
Upside
Reiterated
05/06/26
Barclays Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
William Blair Analyst forecast on IT:1VRTX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Addus Homecare (ADUS), Vertex Pharmaceuticals (VRTX)
Oppenheimer Analyst forecast on IT:1VRTX
Jay Olson
Oppenheimer
Oppenheimer
€516.67
Buy
39.09%
Upside
Reiterated
05/05/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Eli Lilly & Co (LLY)
Needham Analyst forecast on IT:1VRTX
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
05/05/26
Analyst Maintains Hold on Vertex as Strong CF Franchise Offsets Mixed Q1 Results and Non‑CF Pipeline Uncertainty
Evercore ISI Analyst forecast on IT:1VRTX
Cory Kasimov
Evercore ISI
Evercore ISI
€456.39→€460.69
Buy
24.03%
Upside
Reiterated
05/05/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Evercore ISI
Stifel Nicolaus Analyst forecast on IT:1VRTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€401.28
Hold
8.03%
Upside
Reiterated
05/05/26
Stifel Nicolaus Remains a Hold on Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on IT:1VRTX
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€376.31→€375.44
Hold
1.08%
Upside
Reiterated
05/05/26
Vertex Pharmaceuticals price target lowered to $436 from $437 at CanaccordVertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
Morgan Stanley Analyst forecast on IT:1VRTX
Terence Flynn
Morgan Stanley
Morgan Stanley
€527→€530.44
Buy
42.80%
Upside
Assigned
05/05/26
Morgan Stanley Remains a Buy on Vertex Pharmaceuticals (VRTX)
TD Cowen Analyst forecast on IT:1VRTX
Phil Nadeau
TD Cowen
TD Cowen
€452.08
Buy
21.71%
Upside
Reiterated
05/05/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Evolus (EOLS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months
Mohit BansalWells Fargo
Success Rate
22/31 ratings generated profit
71%
Average Return
+6.91%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 70.97% of your transactions generating a profit, with an average return of +6.91% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
23/33 ratings generated profit
70%
Average Return
+12.26%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 69.70% of your transactions generating a profit, with an average return of +12.26% per trade.
2 Years
Michael YeeUBS
Success Rate
24/30 ratings generated profit
80%
Average Return
+22.43%
Copying Michael Yee's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +22.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1VRTX Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
50
56
45
42
28
Hold
7
11
13
11
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
57
67
58
53
35
In the current month, 1VRTX has received 28 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 1VRTX average Analyst price target in the past 3 months is 485.46.
Each month's total comprises the sum of three months' worth of ratings.

1VRTX Financial Forecast

1VRTX Earnings Forecast

Next quarter’s earnings estimate for 1VRTX is €4.09 with a range of €3.46 to €4.47. The previous quarter’s EPS was €3.87. 1VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1VRTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1VRTX is €4.09 with a range of €3.46 to €4.47. The previous quarter’s EPS was €3.87. 1VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1VRTX has Performed in-line its overall industry.

1VRTX Sales Forecast

Next quarter’s sales forecast for 1VRTX is €2.79B with a range of €2.70B to €2.87B. The previous quarter’s sales results were €2.61B. 1VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1VRTX has Performed in-line its overall industry.
Next quarter’s sales forecast for 1VRTX is €2.79B with a range of €2.70B to €2.87B. The previous quarter’s sales results were €2.61B. 1VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1VRTX has Performed in-line its overall industry.

1VRTX Stock Forecast FAQ

What is IT:1VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals Inc.’s 12-month average price target is 485.46.
    What is IT:1VRTX’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals Inc. has 30.69% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Vertex Pharmaceuticals Inc. a Buy, Sell or Hold?
          Vertex Pharmaceuticals Inc. has a consensus rating of Strong Buy, which is based on 20 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Vertex Pharmaceuticals Inc.’s share price target?
            The average share price target for Vertex Pharmaceuticals Inc. is 485.46. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €551.97 ,and the lowest forecast is €375.44. The average share price target represents 30.69% Increase from the current price of €371.45.
              What do analysts say about Vertex Pharmaceuticals Inc.?
              Vertex Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.
                How can I buy shares of Vertex Pharmaceuticals Inc.?
                To buy shares of IT:1VRTX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.